Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

865 results

• TOP1201 IPIIndependent statistical analysis of Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 24NCT01820754
• Torlak-300Independent statistical analysis of Phase 3 Trial of Serbian Seasonal Influenza Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02935192).Phase 3Results postedn = 480NCT02935192
• TRACEIndependent statistical analysis of Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 108NCT03078907
• TRAIL1An independent statistical analysis of TRAIL1, a randomized phase 2 study of pirfenidone versus placebo in patients with rheumatoid arthritis interstitial lung disease, including the composite FVC-or-death endpoint and its statistical interpretation.Phase 2Results postedn = 123NCT02808871
• TRANSFORMIndependent statistical analysis of the TRANSFORM trial of endoscopic lung volume reduction with Zephyr valves in patients with COPD and heterogeneous emphysema, including trial design, the primary FEV1 responder endpoint, planned analysis,…Phase NAn = 97NCT02022683
• TRANSIT-1Independent statistical analysis of the phase 3 TRANSIT-1 study evaluating the tolerability and safety of transitioning patients with pulmonary arterial hypertension from inhaled treprostinil to oral selexipag.Phase 3Results postedn = 34NCT02471183
• TREAT-COVIDIndependent statistical analysis of TREAT-COVID (NCT04351516), a randomized phase 2/3 trial evaluating hydroxychloroquine versus placebo in older adults with COVID-19. Includes trial design, endpoints, planned methodology, and statistical interpretation.Phase 2/3NCT04351516
• TremelimumabIndependent statistical analysis of Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 571NCT01843374
• TRILOGYIndependent statistical analysis of Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 1,368NCT01917331
• TRIUMPH-2Independent statistical analysis of TRIUMPH-2, a randomized, double-blind phase 3 study of retatrutide in participants with type 2 diabetes mellitus who have obesity or overweight.Phase 3n = 1,152NCT05929079
• URIDxEDIndependent statistical analysis of Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02957136).Phase NAResults postedn = 194NCT02957136
• VENTUREIndependent statistical analysis of the VENTURE phase 3 trial evaluating dupilumab in patients with severe steroid-dependent asthma, including its randomized design, oral corticosteroid reduction endpoints, ANCOVA, logistic regression, missing-data methods, and reported…Phase 3Results postedn = 210NCT02528214
• VPCIndependent statistical analysis of Co-Design and Pilot Testing of Peer-led Community Outreach to Improve Equity, Veteran-Centeredness and Uptake of Lung Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 3NCT06389981
• WAVEIndependent statistical analysis of Durvalumab Long-Term Safety and Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04078152).Phase 4Results postedn = 163NCT04078152
• ZENITHIndependent statistical analysis of A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH): primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 173NCT04896008

← All therapeutic areas